Wolfe Research on Apellis Pharmaceuticals (APLS): Biogen deal 'makes sense' at 'good time to sell'
Wolfe Research analyst Andy Chen reiterated a Peerperform rating on Apellis Pharmaceuticals (NASDAQ: APLS)The analyst commented, "This morning, Biogen announced ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)